Martinsried, Germany, October 15, 2008 /b3c newswire / - KINAXO Biotechnologies GmbH announced today that it has entered into strategic sales and marketing partnerships with BioCatalyst International and BioFocus DPI to support the introduction of KINAXO’s proprietary Cellular Target Profiling™ Service within the US and Japanese market.
The KINAXO Cellular Target Profiling Service enables drug developers to determine the native cellular protein interactions of small molecule compounds in a physiological setting. This provides significant benefits to any drug development program, since knowledge of the compound’s proteome-wide on/off-target activities supports the prediction of its performance in clinical trials.
KINAXO chose to partner with BioCatalyst and BioFocus DPI due to their hands-on experience in supporting high value drug discovery services. Both partners will work closely with the KINAXO management and scientific team to ensure qualified, personalized support in the US and Japan.
BioCatalyst International, a New York based company, specializes in the introduction and development of early market drug discovery products and services. BioCatalyst maintains a team of experienced PhD scientist and business development associates to properly communicate and support all the high value aspects of KINAXO’s Cellular Target Profiling Service. This will allow KINAXO to serve its US customers with direct, local support.
In Japan, KINAXO has partnered with BioFocus DPI, a global drug discovery service provider with headquarters in the United Kingdom. BioFocus DPI offers a range of target-to-drug discovery products and services to support pharmaceutical companies in their drug development process. BioFocus DPI will help KINAXO establish a wide presence in Japan through its broad network of pharmaceutical relationships and intimate knowledge of the Japanese market.
Dr. Andreas Jenne, KINAXO’s CEO commented: “The pharmaceutical industry is very much a global industry and thus it is critical to rapidly establish a presence in the major markets. Our sophisticated services require that we partner with organizations that fully understand both the high value information we offer and the particular needs of drug developers. We are very excited about working with BioCatalyst and BioFocus DPI to better serve our customers in the US and Japan.”
About KINAXO www.kinaxo.com
KINAXO Biotechnologies is a privately-held biotechnology company based in Munich/Martinsried, Germany. As a spin-off of the Max Planck Institute of Biochemistry in Martinsried, KINAXO offers extensive experience in cellular target profiling with several ongoing pharmaceutical and biotechnology company collaborations, e.g. with Boehringer Ingelheim, Johnson & Johnson and Takeda. KINAXO is financed by European investors BioM, High-Tech Gründerfonds, KfW, Max Planck Society, and Mountain Partners.
KINAXO’s Cellular Target Profiling™ Service delivers direct insight into a small molecule’s quantitative binding properties (KD values) across the proteome of a given cell line or tissue sample. This interaction profile provides critical guidance within applications such as lead compound selection for clinical trials, drug repositioning, target deconvolution, and off-target toxicity investigations.
About BioCatalyst www.biocatalystintl.com
Based in Florida and New York, BioCatalyst International partners with early stage life science companies to prepare and implement a successful product launch into the US drug discovery market. BioCatalyst helps the transition to an aggressive growth strategy that will contribute significant long term value to the business. BioCatalyst can assist European startups to pursue a direct global customer reach without the need to establish a full time subsidiary. Our founding principal, Sheridan Snyder, is among the most recognized names in the life science industry and has built some of the world’s leading biotechnology companies, including Genzyme, Biotage/Dyax, and Upstate Cell Signaling Solutions.
About BioFocus DPI www.biofocusdpi.com
BioFocus DPI aims to expand its partners’ drug pipelines by accelerating the gene-to-candidate discovery process. This is achieved through a comprehensive discovery platform, which includes target discovery in human primary cells, focused as well as diverse compound libraries, in vitro and cell-based screening, medicinal chemistry, structural biology and ADME/PK services, supported by unique informatics tools. As the service division of Galapagos, BioFocus DPI has over 300 laboratory-based employees in four countries worldwide.
Dr. Andreas Jenne
Managing Director, CEO
KINAXO Biotechnologies GmbH
Am Klopferspitz 19a
82152 Martinsried, Germany
Phone: +49 89 461 33 63 11